Retained Earnings (Accumulated Deficit) in USD of Ambrx Biopharma Cayman, Inc. from Q4 2020 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Ambrx Biopharma Cayman, Inc. quarterly Retained Earnings (Accumulated Deficit) history and change rate from Q4 2020 to Q2 2023.
  • Ambrx Biopharma Cayman, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending 30 Jun 2023 was $324,756,000, a 22% decline year-over-year.
Source SEC data
View on sec.gov
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

Ambrx Biopharma Cayman, Inc. Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2023 $324,756,000 -$59,635,000 -22% 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 $306,930,000 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $291,628,000 -$77,996,000 -37% 31 Dec 2022 10-Q 09 Aug 2023 2023 Q2
Q2 2022 $265,121,000 30 Jun 2022 6-K 29 Aug 2022 2022 Q2
Q4 2021 $213,632,000 -$68,079,000 -47% 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q4 2020 $145,553,000 31 Dec 2020 20-F 26 Apr 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.